Elsevier's Maturitas Publishes Position Statement on Fertility Preservation
Amsterdam, November 6, 2013
a world-leading provider of scientific, technical and medical information
products and services, today announced the publication of a position statement
by the European
Menopause and Andropause Society (EMAS)
in the journal Maturitas on the topic of fertility preservation.
The rising need for fertility preservation results from two new 21st century changes. Improved survival of malignant disease with gonadotoxic treatments means that long-term reproductive potential should now be considered. Delaying childbirth means that the use of fertility preservation techniques to counter the normal age-related decline in fertility is also becoming a topic of interest for many healthy women.
This EMAS position paper provides and critically appraises evidence on available options for fertility preservation in both pre-pubertal and post-pubertal men and women. EMAS position paper recommends that all men and women of reproductive age should be thoroughly informed before the initiation of any gonadotoxic treatment about the possible risks of the treatment in question and all available options of fertility preservation should be discussed. Fertility preservation should be a priority when treating children or adults of reproductive age with agents that may have hazardous effects on the reproductive system and gonadotoxicity should be kept at a minimum.
These and other recommendations presented in the EMAS' position statement on fertility preservation are published in the article: "EMAS Position statement: Fertility preservation," published in Maturitas, Elsevier; available online on ScienceDirect.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact firstname.lastname@example.org Journalists wishing to interview the authors may contact Greyling Peoples, +31 20 485 3323; email@example.com or editor of Maturitas, Margaret Rees firstname.lastname@example.org.
"EMAS Position statement: Fertility preservation" by Gesthimani Mintziori, Irene Lambrinoudaki, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Faustino R. Pérez-López, Karin Schenck-Gustafsson, Yvonne van der Schouw, Tommaso Simoncini, Florence Tremollieres, Basil C. Tarlatzis, Margaret Rees and Dimitrios G. Goulis. Published in Maturitas (Elsevier), In Press; DOI: 10.1016/j.maturitas.2013.10.010.
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date.www.emas-online.org
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 3323